drugset / Trial / NCT06042764
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
Timeline
- Start
- 2023-08-31
- Primary completion
- 2024-03-01
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SA55 | Protein / enzyme biologic | 300 mg | — |
| Subject | SA55 | Protein / enzyme biologic | 600 mg | — |